Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Topics in Pharmacology   Volumes    Volume 13  Issue 2
Gender differences in response to antidepressants
Shigeru Morishita, Toshihiko Kinoshita
Pages: 51 - 64
Number of pages: 14
Current Topics in Pharmacology
Volume 13  Issue 2

Copyright © 2009 Research Trends. All rights reserved

Epidemiological studies have consistently shown that depression is approximately twice as common in females as in males. There is also some evidence that there are gender differences in the clinical manifestations. Some studies have addressed the epidemiological and pharmacological implications of gender-associated differences in the overall treatment response to antidepressants in clinical practice. Recently, several new antidepressants have become available. However, antidepressants do not have the same effect in all patients all the time. It is important to be able to predict which patients would most likely benefit from particular antidepressants. To examine gender differences in treatment remission in depressed patients treated with fluvoxamine, paroxetine, sertraline, milnacipran, or maprotiline, a retrospective cohort analysis was carried out. Three hundred and sixty-eight patients were identified who had been treated with one of fluvoxamine, paroxetine, sertraline, milnacipran, or maprotiline for depression. This study was done to explore the gender differences in the effect of these antidepressants. Among female patients with depression, the remission rate was higher with sertraline and maprotiline than with fluvoxamine, paroxetine, and milnacipran. Furthermore, authors summarized the gender differences in the effect of other SSRIs (fluoxetine, citalopram), SNRIs (venlafaxin, duloxetine), selective noradrenaline reuptake inhibitor (reboxetine), monoamine oxidase inhibitors (phenelzine, tranylcypromine, L-deprenyl) and noradrenaline dopamine reuptake inhibitor (bupropion), and concluded clinical use of antidepressants for gender.
Buy this Article


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms